Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Meta’s AI organization underwent tremendous change in 2025. After the disappointing debut of its flagship Llama 4 model, ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

Innovation fails when every pilot starts from scratch; the chassis approach shows how to move fast with vendors while keeping ...

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

Here are seven biopharma-related trends for 2026 that have emerged from GEN interviews with experts and other industry stakeholders, and from reviews of reports and public statements.

For many, the festive season conjures images of cosy gatherings, twinkling lights and joyful celebration. But beneath the ...